Pfizer Inc. (NYSE:PFE) Shares Sold by Bokf Na

Bokf Na trimmed its position in Pfizer Inc. (NYSE:PFE) by 29.7% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 201,971 shares of the biopharmaceutical company’s stock after selling 85,332 shares during the period. Bokf Na’s holdings in Pfizer were worth $5,599,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in PFE. Absolute Gestao de Investimentos Ltda. acquired a new stake in shares of Pfizer during the 1st quarter valued at $3,785,000. Kestra Advisory Services LLC lifted its position in shares of Pfizer by 41.3% during the 1st quarter. Kestra Advisory Services LLC now owns 987,256 shares of the biopharmaceutical company’s stock valued at $27,396,000 after acquiring an additional 288,602 shares during the last quarter. Steel Grove Capital Advisors LLC lifted its position in shares of Pfizer by 304.4% during the 1st quarter. Steel Grove Capital Advisors LLC now owns 60,584 shares of the biopharmaceutical company’s stock valued at $1,681,000 after acquiring an additional 45,604 shares during the last quarter. LRI Investments LLC acquired a new stake in shares of Pfizer during the 1st quarter valued at $352,000. Finally, Linscomb Wealth Inc. lifted its position in shares of Pfizer by 1.5% during the 1st quarter. Linscomb Wealth Inc. now owns 229,904 shares of the biopharmaceutical company’s stock valued at $6,380,000 after acquiring an additional 3,297 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Up 3.3 %

Shares of NYSE PFE traded up $1.00 during mid-day trading on Friday, reaching $30.77. The company had a trading volume of 35,657,080 shares, compared to its average volume of 30,301,530. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $37.19. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05. The stock has a market capitalization of $174.36 billion, a PE ratio of -512.75, a price-to-earnings-growth ratio of 1.20 and a beta of 0.69. The stock’s 50 day moving average is $28.54 and its 200-day moving average is $27.76.

Pfizer (NYSE:PFE) last posted its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping the consensus estimate of $0.56 by $0.26. The firm had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The business’s quarterly revenue was down 19.5% on a year-over-year basis. During the same period in the prior year, the business posted $1.23 earnings per share. As a group, equities analysts anticipate that Pfizer Inc. will post 2.38 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 5.46%. The ex-dividend date is Friday, July 26th. Pfizer’s payout ratio is -2,799.53%.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Morgan Stanley increased their price objective on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday, May 2nd. Barclays increased their target price on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 10th. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Wednesday, July 10th. Finally, BMO Capital Markets restated an “outperform” rating and issued a $36.00 target price (up previously from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Nine research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, Pfizer presently has an average rating of “Hold” and an average target price of $34.50.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.